MVision’s AI segmentation service has been updated and now supports new Lung SABR protocol and MRI Male Pelvis protocol MR-only workflow

Helsinki – June 8, 2021 – MVision will be releasing an important update to segmentation service that standardizes organ-at-risk contouring and automates segmentation in radiotherapy to streamline cancer treatment planning. The update is scheduled to take place between June 12th-June 13th.

MVisions’ Chief Product Officer and medical physicist, Jarkko Niemelä, further emphasized the importance of the new lung CT model, stating that, “During the pandemic, there has been a growing need for shorter and more efficient radiation therapy. Many lung cancer patient groups can be treated with stereotactic radiotherapy where, instead of conventional 20 to 33 visits, the patient has 3 or 4 treatment fractions. We wanted to support this growing need and developed a SABR Consortium guideline compliant lung CT auto-segmentation model.”

The update will include 2 segmentation models:

  • An advanced lung CT model following the lung SABR protocol
  • A Male pelvis MRI model for MRI-only treatment planning workflow supporting major MRI scanners

Furthermore, additions will be made to existing models, including the:

  • Male pelvis CT: Kidneys
  • Abdomen-lung CT: SpinalCord
  • Breast CT: Carotids, Thyroid and SpinalCord
  • Female pelvis CT: Bony structures and bowels

Mahmudul Hasan, MVision AI’s co-founder and CEO, expressed his excitement in the new release of the Lung and pelvis models. He disclosed that, “the new Lung SABR and MR pelvis model (MR-only) release is a significant milestone to support SBRT and MR Only workflow. I am thankful to our existing partners and the team for delivering this within a short period of time.”

For more information on the MVision AI Segmentation Service 1.2.1, contact Dr. Britta Schürmann, Head of Sales Development, EMEA.

About MVision AI:

MVision is a Helsinki-based company operating globally. The company was born out of a deep desire to harness AI in winning the war on cancer. MVision AI exists to provide clinicians with the finest, most reliable tools to improve clinicians’ workflow and help them to focus on patient care.

For more information, contact MVision AI

c/o Terkko Health Hub, Haartmaninkatu 4, 00290 Helsinki, Finland.

Tel: +358 (0) 40 5489 229

Email: info (at)


+358 40 500 7915; pr (at)

Our Newsletter

Subscribe to get information, latest news and other interesting offers about MVision AI

Related Posts


World Cancer Day – Joining efforts for a better cancer care

World cancer day, celebrated on the 4th of February, was established more than 20 years ago. It represents an initiative of the Union for International Cancer Control (UICC) , the oldest and largest global membership organization dedicated to taking action on cancer. UICC has over 1150 member organizations in 172…



How can AI-based auto-contouring improve the life of patients who need palliative radiation therapy?

Cancer is one of the leading causes of morbidity and death, worldwide. Approximately 18 million people are diagnosed with cancer each year and the number is expected to increase. Pain is experienced by two thirds of patients having advanced, metastatic or terminal disease (1). Other symptoms caused by compression on…



MVision AI Announces Partnership with Medron Medical Systems (Canada)

HELSINKI, Finland - January 22, 2024 MVision AI, a premier software service provider of GBS™ (Guideline-Based Segmentation) solution for same-day radiotherapy treatment planning, proudly announces a new distribution partnership with Medron Medical Systems, a leading health equipment provider in Canada. This collaboration follows the receipt of Medical Device License (MDL)…

Press Releases